Background:The association between HCV infection and atherosclerotic coronary heart disease (CHD) remains unclear. The aim of this study was the detection of the effect of HCV seropositivity on outcome of percutaneous coronary intervention. Methods: This prospective study was conducted on 150-patients candidate for elective PCI in Benha University Hosppital and National Heart Institute from April 2021 to March 2022; the participants were classified into three equal groups: Group 1: HCV seropositive not received antiviral treatment. Group 2: HCV seropositive, received antiviral treatment & became –ve PCR. Group 3 (control) HCV seronegative.
Results:There was statistically significant difference between the three studied groups regarding Gensini score which was significantly higher in group1.patients in group 1 had higher number of diseased vessels and implanted stents , but without statistical significance. The difference between the three studied groups regarding stent length, stent diameter and dilatation pressure was statistically insignificant. patients in group 1 had higher cumulative incidence of MACEs such as TLR, MI, CVS, major bleeding, non-cardiac death than group 2 and 3 after 1, 3 and 6 months of clinical follow up but this difference was not statistically significant.
Conclusion: HCV seropositivity has a slight impact on the cardiovascular outcomes (TLR, TVR, MI, CVS, stent thrombosis, major bleeding, CABG, cardiac or non-cardiac death), or In-stent restenosis following PCI.